Open Access

SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway

  • Authors:
    • Bin Zhu
    • Dongdong Cheng
    • Lei Hou
    • Shumin Zhou
    • Tao Ying
    • Qingcheng Yang
  • View Affiliations

  • Published online on: March 27, 2017     https://doi.org/10.3892/or.2017.5530
  • Pages: 2575-2582
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Growing evidence indicates that SLC3A2 (solute carrier family 3 member 2) is upregulated and correlates with tumor growth in multiple types of cancers, while the role of SLC3A2 in human osteosarcoma (OS) is rarely discussed. Thus, the aim of the present study was to demonstrate the expression of SLC3A2 in human osteosarcoma and reveal its biological function and the underlying mechanisms. RT-PCR, western blot analysis and immunohistochemistry (IHC) were used to assess the expression of SLC3A2 in OS samples and cell lines. Cell cycle, Cell Counting Kit-8 (CCK-8) and colony formation assays were used to test the cell survival capacity. To investigate the potential mechanism by which SLC3A2 regulates OS growth, we used a slide-based antibody array. We demonstrated that SLC3A2 was upregulated in OS cell lines as well as OS tissues. High expression of SLC3A2 was correlated with clinical stage and tumor size in OS. Reduced expression of SLC3A2 inhibited OS cell proliferation through G2/M phase arrest. Most importantly, we found that SLC3A2 may regulate OS growth through the PI3K/Akt signaling pathway. In conclusion, SLC3A2 is upregulated in OS and plays a crucial role in tumor growth. Targeting SLC3A2 may provide a new therapeutic strategy for OS.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 37 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu B, Cheng D, Hou L, Zhou S, Ying T and Yang Q: SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway. Oncol Rep 37: 2575-2582, 2017
APA
Zhu, B., Cheng, D., Hou, L., Zhou, S., Ying, T., & Yang, Q. (2017). SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway. Oncology Reports, 37, 2575-2582. https://doi.org/10.3892/or.2017.5530
MLA
Zhu, B., Cheng, D., Hou, L., Zhou, S., Ying, T., Yang, Q."SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway". Oncology Reports 37.5 (2017): 2575-2582.
Chicago
Zhu, B., Cheng, D., Hou, L., Zhou, S., Ying, T., Yang, Q."SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway". Oncology Reports 37, no. 5 (2017): 2575-2582. https://doi.org/10.3892/or.2017.5530